Correction

Proprotein convertase subtilisin/Kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation (vol 291, pg 16659, 2016)

JOURNAL OF BIOLOGICAL CHEMISTRY (2016)

Journal

JOURNAL OF BIOLOGICAL CHEMISTRY

Volume 291, Issue 51, Pages 26586-26586

Publisher

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC

DOI: 10.1074/jbc.A116.717736

Keywords

-

Categories

Biochemistry & Molecular Biology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Recommended

Article Biochemistry & Molecular Biology

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis

Vittoria Cammisotto, Francesco Baratta, Paola G. Simeone, Cristina Barale, Enrico Lupia, Gioacchino Galardo, Francesca Santilli, Isabella Russo, Pasquale Pignatelli

Summary: PCSK9 is involved in cholesterol metabolism and plays a role in the development of atherosclerosis and atherothrombotic processes, promoting plaque formation and oxidative stress.

ANTIOXIDANTS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression

Coen van Solingen, Scott R. Oldebeken, Alessandro G. Salerno, Amarylis C. B. A. Wanschel, Kathryn J. Moore

Summary: The discovery of PCSK9 and its role in LDL regulation has led to the rapid development of therapeutic PCSK9 inhibitors. Research has identified certain microRNAs that can reduce PCSK9 expression, leading to increased LDLR expression in hepatic cells, which may have therapeutic implications for manipulating LDLR expression and cholesterol levels in the liver.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Article Medical Laboratory Technology

Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum

Antonin Jabor, Tereza Vackova, Zdenek Kubicek, Jitka Komrskova, Marek Protus, Janka Franekova

Summary: The study evaluated the biological variation of serum PCSK9, finding a high within-subject variability in healthy individuals, suggesting that common reference intervals can be used to interpret its values.

CLINICA CHIMICA ACTA (2021)

Add to Collection

Article Medical Laboratory Technology

Insight into the role of PCSK9 in glucose metabolism

Jia-ni Xu, Ting-ting Wang, Hong Shu, Shun-yi Shi, Li-chan Tao, Jian-Jun Li

Summary: Diabetes mellitus (DM) is strongly associated with atherosclerotic cardiovascular disease (ASCVD), and the protein PCSK9 has been identified as a key regulator of LDL-C levels and a potential target for improving cardiovascular outcomes. Recent studies have also linked PCSK9 to glucose metabolism, and clinical trials suggest that PCSK9 inhibitors are more effective in treating patients with DM. This review summarizes the current findings on the association between PCSK9 and glucose metabolism, including the effects of PCSK9 genetic mutations, plasma PCSK9 concentrations, and glucose-lowering drugs on metabolic parameters, as well as the impact of PCSK9 inhibitors on cardiovascular outcomes in patients with DM.

CLINICA CHIMICA ACTA (2023)

Add to Collection

Article Medicine, General & Internal

Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy

Jonathan Grimm, Georg Peschel, Martina Mueller, Doris Schacherer, Reiner Wiest, Kilian Weigand, Christa Buechler

Summary: This study found that serum PCSK9 levels were associated with liver injury and inflammation in cirrhotic HCV patients, but not with LDL levels. After DAA therapy, PCSK9 decreased and LDL increased in non-cirrhotic HCV patients, while no changes were observed in the cirrhotic group.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

The predictive utility of circulating PCSK9 levels on diabetes mellitus

Jia Peng, Cheng-Gang Zhu, Jian-Jun Li

Summary: Increasing data suggest that PCSK9 may play a role in the development of type 2 diabetes and be associated with clinical outcomes in diabetic patients, but there is currently no general agreement about the association of PCSK9 with T2DM. The utility of circulating PCSK9 concentration as a predictor for the risk of new-onset T2DM should be considered clinically prudent.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Sex difference in circulating PCSK9 and its clinical implications

Fang Jia, Si-Fan Fei, De-Bing Tong, Cong Xue, Jian-Jun Li

Summary: PCSK9 increases circulating LDL-C levels by degrading LDL receptors and has direct effects on atherosclerosis and coronary plaque inflammation. Emerging data show higher PCSK9 concentrations in women than men, suggesting potential sex differences in PCSK9 roles and clinical implications.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Immunology

PCSK9 inhibition ameliorates experimental autoimmune myocarditis by reducing Th17 cell differentiation through LDLR/STAT-3/ROR-γt pathway

Miao Yu, Wenjing Tang, Wei Liang, Baikang Xie, Ran Gao, Peiwu Ding, Xiaoying Gu, Min Wang, Shuang Wen, Peng Sun

Summary: Proprotein convertase subtilisin kexin type 9 (PCSK9) was initially known for its role in regulating cholesterol metabolism, but recent studies have shown its involvement in inflammatory and autoimmune diseases unrelated to cholesterol alterations. This study aims to investigate the roles and mechanisms of PCSK9 in myocarditis and found that PCSK9 inhibition can ameliorate the severity of myocarditis by reducing Th17 cell differentiation. PCSK9 appears to be a promising target for treating myocarditis.

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

Add to Collection

Article Cell Biology

Anti-PCSK9 Treatment Attenuates Liver Fibrosis via Inhibiting Hypoxia-Induced Autophagy in Hepatocytes

Liuxin Ning, Yanting Zou, Shuyu Li, Yue Cao, Beili Xu, Shuncai Zhang, Yu Cai

Summary: The study aimed to investigate the mechanism of anti-PCSK9 treatment on liver fibrosis by inhibiting hypoxia-induced autophagy. The results showed that anti-PCSK9 treatment could alleviate liver inflammation and fibrosis by regulating the AMPK/mTOR/ULK1 signaling pathway to reduce hypoxia-induced autophagy in hepatocytes.

INFLAMMATION (2023)

Add to Collection

Review Integrative & Complementary Medicine

Research on Hepatocyte Regulation of PCSK9-LDLR and Its Related Drug Targets

Su-su Liu, Tong Yu, Yan-fang Qiao, Shu-xiao Gu, Xin-lou Chai

Summary: The prevalence of hyperlipidemia has increased significantly due to various factors and has become a common pathological condition. High circulating LDL-C is one of the causes of hyperlipidemia. LDL-C regulates cholesterol homeostasis through binding to LDLR, while PCSK9 mediates LDLR degradation, leading to hyperlipidemia. Targeting PCSK9-synthesizing transcription factors and downstream molecules is important for developing new lipid-lowering drugs.

CHINESE JOURNAL OF INTEGRATIVE MEDICINE (2023)

Add to Collection

Article Endocrinology & Metabolism

Correlation Between Circulating PCSK9 Levels and Gestational Diabetes Mellitus in a Chinese Population

Yiming Wu, Jie Shi, Qing Su, Zhen Yang, Li Qin

Summary: This study found that circulating PCSK9 levels were significantly higher in pregnant women with gestational diabetes mellitus (GDM) compared to those with normal glucose tolerance. The levels of PCSK9 were positively correlated with fasting plasma glucose, glycated hemoglobin, total cholesterol, and low-density lipoprotein cholesterol in the GDM group. Logistic regression analysis showed that age and serum PCSK9 levels were independently associated with GDM. The study suggests a potential link between PCSK9 and GDM.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

PCSK9 causes inflammation and cGAS/STING pathway activation in diabetic nephropathy

Zhicai Feng, Xiangyu Liao, Juan Peng, Jingjing Quan, Hao Zhang, Zhijun Huang, Bin Yi

Summary: Our research demonstrates that PCSK9 contributes to aggravated inflammation in the kidneys through triggering mitochondrial DNA damage and activating the cGAS-STING signaling pathway in diabetic nephropathy (DN). Inhibiting PCSK9 with mAbs or siRNA effectively reduces inflammation and delays the progression of DN. Furthermore, the inhibition of STING significantly blocks the inflammation triggered by HGPA in HK-2 cells.

FASEB JOURNAL (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Modulation of vascular endothelial inflammatory response by proprotein convertase subtilisin-kexin type 9

Alex K. K. Leung, Yuan Chao Xue, Antyrah de Guzman, Guilherme Grzelkovski, HyeJin Julia Kong, Kelly R. Genga, James A. Russell, John H. Boyd, Gordon A. Francis, Keith R. Walley

Summary: This study found that PCSK9 reduces the uptake of LPS in vascular endothelial cells through LDLR-mediated endocytosis, leading to a decrease in the inflammatory response. This suggests that PCSK9 inhibition may have additional effects on vascular endothelial inflammation.

ATHEROSCLEROSIS (2022)

Add to Collection

Article Peripheral Vascular Disease

Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population

Hitoshi Hamamura, Hisashi Adachi, Mika Enomoto, Ako Fukami, Sachiko Nakamura, Yume Nohara, Nagisa Morikawa, Akiko Sakaue, Kenta Toyomasu, Maki Yamamoto, Yoshihiro Fukumoto

Summary: In a general population sample, serum PCSK9 levels are independently associated with triglycerides, Lp(a) levels, and HOMA-IR, but not with LDL-C levels.

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2021)

Add to Collection

Article Medicine, General & Internal

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome

Thomas S. Metkus, Bo Soo Kim, Steven R. Jones, Seth S. Martin, Steven P. Schulman, Thorsten M. Leucker

Summary: This study aimed to investigate the association between proprotein convertase subtilisin/kexin type 9 (PCSK9) and mortality and ICU outcomes in patients with acute respiratory distress syndrome (ARDS). The results showed that PCSK9 levels were not associated with mortality in ARDS patients, but higher PCSK9 levels were associated with fewer ICU and ventilator free days.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Article Medicine, Research & Experimental

The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury

Paul F. Lebeau, Hanny Wassef, Jae Hyun Byun, Khrystyna Platko, Brandon Ason, Simon Jackson, Joshua Dobroff, Susan Shetterly, William G. Richards, Ali A. Al-Hashimi, Kevin Doyoon Won, Majambu Mbikay, Annik Prat, An Tang, Guillaume Pare, Renata Pasqualini, Nabil G. Seidah, Wadih Arap, Michel Chretien, Richard C. Austin

Summary: Individuals carrying the PCSK9(Q152H) variation have low cholesterol levels and normal liver function despite retaining the uncleavable form of PCSK9 in liver cells. Overexpression of PCSK9(Q152H) in mice unexpectedly protected against ER stress and liver injury, suggesting a potential hepatoprotective role of this variant. This study provides insights into the protective effects of PCSK9(Q152H) on liver function and suggests implications for ER stress-related conditions.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice

Marie-Line Peyot, Anna Roubtsova, Roxane Lussier, Ann Chamberland, Rachid Essalmani, S. R. Murthy Madiraju, Nabil G. Seidah, Marc Prentki, Annik Prat

Summary: PCSK9 plays a crucial role in cholesterol homeostasis, but loss of beta-cell PCS9 does not have any detrimental effects on glucose homeostasis and insulin secretion in mice.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2021)

Add to Collection

Article Multidisciplinary Sciences

Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance

Paul F. Lebeau, Jae Hyun Byun, Khrystyna Platko, Paul Saliba, Matthew Sguazzin, Melissa E. MacDonald, Guillaume Pare, Gregory R. Steinberg, Luke J. Janssen, Suleiman A. Igdoura, Mark A. Tarnopolsky, S. R. Wayne Chen, Nabil G. Seidah, Jakob Magolan, Richard C. Austin

Summary: Caffeine inhibits the activation of SREBP2 to promote LDLc clearance and reduce the risk of cardiovascular disease.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Cell & Tissue Engineering

PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs

Meryl Roudaut, Salam Idriss, Amandine Caillaud, Aurore Girardeau, Antoine Rimbert, Benoite Champon, Amandine David, Antoine Leveque, Lucie Arnaud, Matthieu Pichelin, Xavier Prieur, Annik Prat, Nabil G. Seidah, Kazem Zibara, Cedric Le May, Bertrand Cariou, Karim Si-Tayeb

Summary: PCSK9, a key regulator of LDL cholesterol metabolism, is found to be highly expressed in undifferentiated hiPSCs. Inhibition of PCSK9 in hiPSCs leads to decreased phosphorylation of SMAD2 and cell proliferation, while overexpression of PCSK9 stimulates cell proliferation by regulating the expression of DACT2, an endogenous inhibitor involved in TGF beta-R1 lysosomal degradation. This highlights a new role of PCSK9 in cellular proliferation and development.

STEM CELL REPORTS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a)

Justin R. Clark, Matthew Gemin, Amer Youssef, Santica M. Marcovina, Annik Prat, Nabil G. Seidah, Robert A. Hegele, Michael B. Boffa, Marlys L. Koschinsky

Summary: Elevated plasma lipoprotein(a) (Lp(a)) is an independent, causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Sortilin may play a role in determining plasma levels of Lp(a) and is associated with the secretion of apo(a) and apoB.

JOURNAL OF LIPID RESEARCH (2022)

Add to Collection

Article Virology

Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity

Rachid Essalmani, Jaspreet Jain, Delia Susan-Resiga, Ursula Andreo, Alexandra Evagelidis, Rabeb Mouna Derbali, David N. Huynh, Frederic Dallaire, Melanie Laporte, Adrien Delpal, Priscila Sutto-Ortiz, Bruno Coutard, Claudine Mapa, Keith Wilcoxen, Etienne Decroly, Tram Nq Pham, Eric A. Cohen, Nabil G. Seidah

Summary: The spike protein of SARS-CoV-2 plays a crucial role in infecting the lungs and other tissues by binding to the ACE2 receptor. Cleavage of the spike protein at S1/S2 and S2' sites is important for viral entry and fusion. This study identifies the fusion activation site S2' as KPSKR815 down arrow and demonstrates that its cleavage is enhanced by ACE2 engagement. The combination of furin and TMPRSS2 inhibitors shows promise as potent antivirals against SARS-CoV-2.

JOURNAL OF VIROLOGY (2022)

Add to Collection

Review Peripheral Vascular Disease

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond

Nabil G. Seidah, Damien Garcon

Summary: Since the discovery of PCSK9 in 2003, it has been found to play roles not only in regulating LDL-cholesterol, but also in inflammation, pathogen infections, and cellular proliferation in various cancers and associated metastases.

CURRENT ATHEROSCLEROSIS REPORTS (2022)

Add to Collection

Article Engineering, Biomedical

Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors

Jessie R. Davis, Xiao Wang, Isaac P. Witte, Tony P. Huang, Jonathan M. Levy, Aditya Raguram, Samagya Banskota, Nabil G. Seidah, Kiran Musunuru, David R. Liu

Summary: Compact adenine base editors (ABEs) encoded within size-optimized genomes of adeno-associated viruses (AAVs) enable therapeutic base editing in mice at low doses and high editing efficiencies, simplifying AAV production and characterization.

NATURE BIOMEDICAL ENGINEERING (2022)

Add to Collection

Correction Engineering, Biomedical

Efficient in vivo base editing via single adenoassociated viruses with size-optimized genomes encoding compact adenine base editors (Jul, 10.1038/s41551-022-00911-4, 2022)

Jessie R. Davis, Xiao Wang, Isaac P. Witte, Tony P. Huang, Jonathan M. Levy, Aditya Raguram, Samagya Banskota, Nabil G. Seidah, Kiran Musunuru, David R. Liu

NATURE BIOMEDICAL ENGINEERING (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Post-Transcriptional Effects of miRNAs on PCSK7 Expression and Function: miR-125a-5p, miR-143-3p, and miR-409-3p as Negative Regulators

Mahshid Malakootian, Parisa Naeli, Seyed Javad Mowla, Nabil G. Seidah

Summary: In this study, the regulatory miRNAs of PCSK7 gene expression were predicted using bioinformatics algorithms. Four miRNAs were identified as potential regulators of PCSK7 expression. The experimental results confirmed the interactions between these miRNAs and PCSK7, and revealed their regulatory effects on PCSK7 expression levels.

METABOLITES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: Role of hepatic cholesterol

Anna Roubtsova, Damien Garcon, Sandrine Lacoste, Ann Chamberland, Jadwiga Marcinkiewicz, Raphael Metivier, Thibaud Sotin, Martine Paquette, Sophie Bernard, Bertrand Cariou, Cedric Le May, Marlys L. Koschinsky, Nabil G. Seidah, Annik Prat

Summary: The study on PCSK9 knockout mice reveals that female mice shed soluble ectodomain of LDLR massively, while male mice rely on high surface LDLR for replenishment. This shedding process is cholesterol-dependent and influenced by hormone levels in female mice.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2022)

Add to Collection

Article Oncology

PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity

Yan Gu, Xiaozeng Lin, Ying Dong, Geoffrey Wood, Nabil G. Seidah, Geoff Werstuck, Pierre Major, Michael Bonert, Anil Kapoor, Damu Tang

Summary: This study found that tumor-derived PCSK9 is closely associated with the development of melanoma and promotes tumor growth by regulating cholesterol metabolism and influencing the immune system. The study also identified PCSK9 as a potential biomarker for predicting the efficacy of immune checkpoint blockade therapy.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Virology

SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2

Rachid Essalmani, Ursula Andreo, Alexandra Evagelidis, Mailys Le Devehat, Oscar Henrique Pereira Ramos, Carole Fruchart Gaillard, Delia Susan-Resiga, Eric A. Cohen, Nabil G. Seidah

Summary: This study investigates the involvement of cholesterol-regulating enzymes SKI-1 and PCSK9 in the entry of SARS-CoV-2. SKI-1 enhances cell-to-cell fusion by activating SREBP-2, while PCSK9 reduces cell-to-cell fusion by promoting the degradation of ACE2. Both SKI-1 and PCSK9 modulate SARS-CoV-2 entry through independent mechanisms.

VIRUSES-BASEL (2023)

Add to Collection

Review Cell Biology

PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity

Malak Alannan, Nabil G. G. Seidah, Aksam J. J. Merched

Summary: Metabolic rewiring and defective immune responses play important roles in many cancers. PCSK9, an atypical enzyme, regulates lipid metabolism by controlling LDLR and other cell surface receptors. Studies have also shown its involvement in the immune system and other physiological activities.

CELLS (2022)

Add to Collection

Letter Biochemistry & Molecular Biology

Surface LDLR is a major receptor for lipoprotein(a) clearance in male mice lacking PCSK9

Anna Roubtsova, Corey A. Scipione, Damien Garcon, Michael B. Boffa, Nabil G. Seidah, Marlys L. Koschinsky, Annik Prat

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.